Kristine Peterson's most recent trade in ArriVent BioPharma Inc. was a trade of 15,502 Non-Qualified Stock Option (right to buy) done . Disclosure was reported to the exchange on June 18, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| ArriVent BioPharma Inc. | Kristine Peterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 15,502 | 15,502 | - | - | Non-Qualified Stock Option (right to buy) | |
| Immunocore Holdings plc - ADR | Kristine Peterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 26,198 | 26,198 | - | - | Share Option (Right to Buy) | |
| Enanta Pharmaceuticals Inc | Kristine Peterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 15,700 | 15,700 | - | - | Stock Option (right to buy) | |
| Immunocore Holdings plc - ADR | Kristine Peterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 14,534 | 14,534 | - | - | Share Option (Right to Buy) | |
| ArriVent BioPharma Inc. | Kristine Peterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Apr 2024 | 28,587 | 28,587 | - | - | Stock Option (right to buy) | |
| Enanta Pharmaceuticals Inc | Kristine Peterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 15,700 | 15,700 | - | - | Stock Option (right to buy) | |
| Immunogen, Inc. | Kristine Peterson | Director | Sale of securities on an exchange or to another person at price $ 28.90 per share. | 30 Nov 2023 | 20,000 | 0 (0%) | 0% | 28.9 | 578,000 | Common Stock |
| Immunogen, Inc. | Kristine Peterson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2023 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Immunogen, Inc. | Peterson Kristine | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.07 per share. | 30 Nov 2023 | 10,000 | 20,000 (0%) | 0% | 13.1 | 130,700 | Common Stock |
| Immunogen, Inc. | Peterson Kristine | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2023 | 10,000 | 0 | - | - | Stock Option (right to buy) | |
| Immunogen, Inc. | Peterson Kristine | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.10 per share. | 30 Nov 2023 | 10,000 | 10,000 (0%) | 0% | 10.1 | 101,000 | Common Stock |
| Immunogen, Inc. | Kristine Peterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 19,597 | 19,597 | - | - | Stock Option (right to buy) | |
| Immunogen, Inc. | Kristine Peterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 13,090 | 13,090 | - | - | Restricted Stock Unit | |
| Enanta Pharmaceuticals Inc | Kristine Peterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 10,800 | 10,800 | - | - | Stock Option (right to buy) | |
| Paratek Pharmaceuticals Inc. | Kristine Peterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 20,000 | 79,000 (0%) | 0% | 0 | Common Stock | |
| Immunogen, Inc. | Kristine Peterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 44,000 | 44,000 | - | - | Stock Option (right to buy) | |
| Immunogen, Inc. | Kristine Peterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 15,000 | 74,954 | - | - | Deferred Share Unit | |
| Enanta Pharmaceuticals Inc | Kristine Peterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Paratek Pharmaceuticals Inc. | Kristine Peterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2022 | 20,000 | 59,000 (0%) | 0% | 0 | Common Stock | |
| Immunogen, Inc. | Kristine Peterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 44,000 | 44,000 | - | - | Stock Option (right to buy) | |
| Immunogen, Inc. | Kristine Peterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 15,000 | 59,954 | - | - | Deferred Share Unit | |
| Enanta Pharmaceuticals Inc | Kristine Peterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Paratek Pharmaceuticals Inc. | Kristine Peterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 9,000 | 39,000 (0%) | 0% | 0 | Common Stock | |
| Paratek Pharmaceuticals Inc. | Kristine Peterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 7,000 | 7,000 | - | - | Stock Option (right to buy) |